Share This Article:

A Review of Endocrine Disorders in Thalassaemia

Abstract Full-Text HTML XML Download Download as PDF (Size:177KB) PP. 25-34
DOI: 10.4236/ojemd.2014.42003    3,947 Downloads   7,701 Views   Citations

ABSTRACT

Endocrine dysfunction in thalassaemia is amongst the most common complication and is principally attributed to excessive iron overload and suboptimal chelation. The prevalence is quite high particularly in multiethnic populations but determining the prevalence is often difficult due to the widespread heterogeneity of the population and timing of exposure to chelation therapy. Disturbances in growth, pubertal development, abnormal gonadal functions, impaired thyroid, parathyroid and adrenal functions, diabetes and disorderly bone growth are commonly encountered. Early detection and institution of appropriate transfusion regimen and chelation therapy and treatment of complications are the keys to managing this population including regular follow. In this article, we review the literature in relation to the various endocrine complications encountered in thalassaemia.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

P. De, R. Mistry, C. Wright, S. Pancham, W. Burbridge, K. Gangopadhayay, T. Pang and G. Das, "A Review of Endocrine Disorders in Thalassaemia," Open Journal of Endocrine and Metabolic Diseases, Vol. 4 No. 2, 2014, pp. 25-34. doi: 10.4236/ojemd.2014.42003.

References

[1] A. A. Shamshirsaz, M. R. Bekheirnia, M. Kamgar, N. Pourzahedgilani, N. Bouzari, M. Habibzadeh, R. Hashemi, A. A. Shamshirsaz, S. Aghakhani, H. Homayoun and B. Larijani, “Metabolic and Endocrinologic Complications in Beta Thalassemia Major: A Muticentre Study in Tehran,” BMC Endocrine Disorders, Vol. 3, No. 1, 2003, p. 4. http://dx.doi.org/10.1186/1472-6823-3-4
[2] A. H. Al-Elq and H. H. Al Sayeed, “Endocrinopathies in Patients with Thalassemia,” Saudi Medical Journal, Vol. 25, No. 10, 2004, pp. 1347-1351.
[3] R. M. Bannerman, “Thalassemia Intermedia, with Iron Overload, Cardiac Failure, Diabetes Mellitus, Hypopituitarism and Porphyrinuria,” American Journal of Medicine, Vol. 42, No. 3, 1967, pp. 476-486.
http://dx.doi.org/10.1016/0002-9343(67)90276-8
[4] N. Cappellini, A. Cohen, A. Eleftheriou, A. Piga and J. Porter, “Guidelines for the Clinical Management of Thalassemia,” Thalassemia International Federation, Strovolos, 2000, pp. 41-49.
[5] G. Costin, M. Kogut, C. B. Hyman and J. Ortega, “Endocrine Abnormalities in Thalassaemia Major,” American Journal of Diseases in Children, Vol. 133, No. 5, 1979, pp. 497-502.
http://dx.doi.org/10.1001/archpedi.1979.02130050041009
[6] M. Brezis, O. Shalev, B. Leibel, J. Berheim and D. Ben Ishay, “Phosphorus Retention and Hypoparathyroidism Associated with Transfusional Iron Overload in Thalassemia,” Mineral Electrolyte Metabolism, Vol. 4, 1980, pp. 57-61.
[7] A. Sabato, V. De Sanctis, G. Atti, L. Capra, B. Bagni and C. Vullo, “Primary Hypothyroidism and the Low T3 Syndrome in Thalassemia Major,” Archives of Diseases in Childhood, Vol. 58, No. 2, 1983, pp. 120-127.
http://dx.doi.org/10.1136/adc.58.2.120
[8] V. De Sanctis, C. Vullo, M. Katz, B. Wonke, A. V. Hoffbrand, A. Di Palma and B. Bagni, “Endocrine Complications in Thalassemia Major,” In: C. D. Buckner, R. P. Gale and G. Lucarelli, Eds., Advances and Controversies in Thalassemia Therapy, Alan Liss, New York, 1989, pp. 77-83.
[9] D. Tiosano and Z. Hochberg, “Endocrine Complications of Thalassaemia,” Journal of Endocrinological Investigation, Vol. 24, 2001, pp. 716-723.
[10] C. Theodoridis, V. Ladis, A. Papatheodorou, H. Berdousi, F. Palamidou, C. Evagelopoulou, K. Athanassaki, O. Konstantoura and C. Kattamis, “Growth and Management of Short Stature in Thalassemia Major,” Journal of Pediatric Endocrinology and Metabolism, Vol. 11, Suppl. 3, 1998, pp. 835-844.
[11] V. De Sanctis, “Growth and Puberty and Its Management in Thalassemia,” Hormone Research, Vol. 58, Suppl. 1, 2002, pp. 72-79. http://dx.doi.org/10.1159/000064766
[12] G. Raiola, M. C. Gallati, V. De Sanctis, M. Caruso Nicoletti, C. Pintor, V. M. Arcuri and C. Anastasi, “Growth and Puberty in Thalassemia Major,” Journal of Pediatric Endocrinology and Metabolism, Vol. 16, Suppl. 2, 2003, pp. 259-266.
[13] L. C. Low, “Growth, Puberty and Endocrine Function in Beta Thalassemia Major,” Journal of Pediatric Endocrinology and Metabolism, Vol. 10, No. 2, 1977, pp. 175-184.
[14] E. Y. Kwan, A. C. Lee, A. M. Li, S. C. Tan, C. F. Chan, Y. L. Lau and L. C. Low, “A Cross Sectional Study of Growth, Puberty and Endocrine Function in Patients of Thalassemia Major in Hong Kong,” Journal of Paediatrics and Child Health, Vol. 31, No. 2, 1995, pp. 83-87.
http://dx.doi.org/10.1111/j.1440-1754.1995.tb00752.x
[15] L. Leger, R. Girot, H. Crosnier, M. C. Postel Vinay and R. Rappaport, “Normal Growth Hormone Response to GH Releasing Hormone in Children with Thalassemia Major before Puberty: A Possible Age Related Effect,” The Journal of Clinical Endocrinology & Metabolism, Vol. 69, No. 2, 1989, pp. 453-456.
http://dx.doi.org/10.1210/jcem-69-2-453
[16] G. De Luca, M. Maggiolini, M. Bria, M. Caracciolo, A. Giomo, M. Salemo, S. Marsico, M. Lanzino, C. Brancati and S. Ando, “GH Secretion in Thalassemia Patients with Short Stature,” Hormone Research, Vol. 44, No. 4, 1995, pp. 158-163. http://dx.doi.org/10.1159/000184617
[17] H. Karamifar, M. Shahriari and G. H. Amirhakimi, “Failure of Puberty and Linear Growth in Beta Thalassemia Major,” Turkish Journal of Hematology, Vol. 22, No. 2, 2005, pp. 65-69.
[18] C. Roth, R. A. Pekrun, M. Bartz, H. Jarry, S. Eber, M. Lakomek and W. Schroter, “Short Stature and Failure of Pubertal Development in Thalassemia Major: Evidence of Hypothalamic Neurosecretory Dysfunction of Growth Hormone Secretion and Defective Pituitary Gonadotropin Secretion,” European Journal of Pediatrics, Vol. 156, No. 10, 1997, pp. 777-783.
http://dx.doi.org/10.1007/s004310050711
[19] A. T. Soliman, M. Elzalabany, M. Amer and A. M. Ansari, “Growth and Pubertal Development in Transfusion Dependant Children and Adolescents with Thalassemia Major and Sickle Cell Disease: A Comparative Study,” Journal of Tropical Pediatrics, Vol. 45, No. 1, 1999, pp. 23-30.
http://dx.doi.org/10.1093/tropej/45.1.23
[20] H. Moayeri and Z. Oloomi, “Prevalence of Growth and Puberty Failure with Respect to Growth Hormone and Gonadotropins Secretion in Beta Thalassemia Major,” Archives of Iranian Medicine, Vol. 9, No. 4, 2006, pp. 329-334.
[21] R. Gulati, V. Bhatia and S. S. Agarwal, “Early Onset of Endocrine Abnormalities in Beta-Thalassemia Major in a Developing Country,” Journal of Pediatric Endocrinology and Metabolism, Vol. 13, No. 6, 2000, pp. 651-656.
http://dx.doi.org/10.1515/JPEM.2000.13.6.651
[22] C. Borgna-Pignatti, P. De Stefano, L. Zonta, C. Vullo, V. De Sanctis, C. Melevendi, A. Naselli, G. Masera, S. Terzoli and V. Gabutti, “Growth and Sexual Maturation in Thalassaemia Major,” Journal of Pediatrics, Vol. 106, No. 1, 1985, pp. 150-155.
http://dx.doi.org/10.1016/S0022-3476(85)80488-1
[23] M. G. Vogiatzi, E. A. Macklin, F. L. Trachtenberg, E. B. Fung, A. M. Cheung, E. Vichinsky, N. Olivieri, M.Kirby, J. L. Kwiatkowski, M. Cunningham, I. A. Holm, M. Fleisher, R. W. Grady, C. M. Peterson, P. J. Giardina and Thalassemia Clinical Research Network, “Differences in the Prevalence of Growth, Endocrine and Vitamin D Abnormalities among the Various Thalassaemia Syndromes in North America,” British Journal of Haematology, Vol. 146, No. 5, pp. 546-556.
[24] R. S. Britton, G. A. Ramm, J. Olynyk, R. Singh, R. O’Neill and B. R. Bacon, “Pathophysiology of Iron Toxicity,” Advances in Experimental Medicine and Biology, Vol. 356, 1994, pp. 239-253.
http://dx.doi.org/10.1007/978-1-4615-2554-7_26
[25] N. Bridge, “Disorders of Puberty: Pubertal Delay and Pubertal Failure,” In: C. G. D. Brook and P. C. Hindmarsh, Eds., Clinical Pediatric Endocrinology, 4th Edition, Blackwell Science, London, 2001, pp. 173-175.
[26] N. Shehadeh, A. Hazani, M. C. Rudolf, I. Peleg, A. Benderly and Z. Hochberg, “Neurosecretory Dysfunction of Growth Hormone Secretion in Thalassemia Major,” Acta Paediatrica Scandinavica, Vol. 79, No. 8-9, 1990, pp. 790-795.
http://dx.doi.org/10.1111/j.1651-2227.1990.tb11556.x
[27] B. Kuo, E. Zaino and M. S. Roginsky, “Endocrine Function in Thalassemia Major,” Journal of Clinical Endocrinology and Metabolism, Vol. 28, No. 6, 1969, pp. 805-808. http://dx.doi.org/10.1210/jcem-28-6-805
[28] C. H. Anoussakis, D. Alexiou, D. Abatzis and G. Bechrakis, “Endocrinological Investigation of Pituitary Gonadal Axis in Thalassemia Major,” Acta Paediatrica Scandinavia, Vol. 66, No. 1, 1977, pp. 49-51.
http://dx.doi.org/10.1111/j.1651-2227.1977.tb07806.x
[29] H. Landau, I. M. Spitz, G. Civadilli and E. A. Rachmilewitz, “Gonadotropin, Thyrotropin and Prolactin Reserve in Beta Thalassemia,” Clinical Endocrinology, Vol. 9, 1978, pp. 163-173.
[30] O. A. Kletzky, G. Cossin, R. P. Marrs, G. Bernstein, C. M. March and D. R. Mishell Jr, “Gonadotropin Insufficiency in Patients with Thalassemia Major,” Journal of Clinical Endocrinology and Metabolism, Vol. 48, No. 6, 1979, pp. 901-905. http://dx.doi.org/10.1210/jcem-48-6-901
[31] M. N. Lassman, R. T. O’Brien, H. A. Pearson, J. K. Wise, R. K. Donabedian and P. Felia, “Endocrine Evaluation in Thalassemia Major,” Annals of the New York Academy of Sciences, Vol. 232, 1974, pp. 226-237.
http://dx.doi.org/10.1111/j.1749-6632.1974.tb20589.x
[32] G. R. Moshtaghi-Kashanian and F. Razavi, “Ghrelin and Leptin Levels in Relation to Puberty and Reproductive Function in Patients with Beta-Thalassemia,” Hormones (Athens), Vol. 8, 2009, pp. 207-213.
[33] R. Chatterjee, M. Katz, T. F. Cox and J. B. Porter, “Prospective Study of the Hypothalamic Pituitary Axis in the Thalassemic Patients Who Developed Secondary Amenorrhea,” Clinical Endocrinology, Vol. 39, 1993, pp. 287-296.
[34] L. Danesi, M. Scacchi, M. De Martin, A. Dubini, P. Massaro, A. T. Majolo, F. Cavagini and E. E. Polli, “Evaluation of Hypothalamic—Pituitary Function in Patients with Thalassemia Major,” Journal of Endocrinological Investigation, Vol. 15, No. 3, 1992, pp. 177-184.
[35] Italian Working Group on Endocrine Complications in Non-Endocrine Disease, “Multicentre Study on Prevalence of Endocrine Complications in Thalassemia Major,” Clinical Endocrinology (Oxf), Vol. 42, No. 6, 1995, pp. 581-586.
http://dx.doi.org/10.1111/j.1365-2265.1995.tb02683.x
[36] M. Caruso-Nicoletti, V. De Sanctis, M. Capra, G. Cardinale, L. Cucia, F. De Gregorio, A. Filosa, M. C. Gallati, A. Lauriola, R. Malizia, A. Mangiagli, F. Massolo, C. Mastrangelo, A. Meo, M. F. Messina, G. Ponzi, G. Raiola, L. Ruggiero, G. Tamborino and A. Saviano, “Short Stature and Body Proportion in Thalassemia,” Journal of Pediatric Endocrinology & Metabolism, Vol. 11, Suppl. 3, 1998, pp. 811-816.
[37] J. P. S. Chern, K. H. Lin, W. Y. Tsai, S. C. Wang, M. Y. Lu, D. T. Lin, K. S. Lin and S. H. Lo, “Hypogonadotropic Hypogonadism and Hematologic Phenotype in Patients with Transfusion Dependant Beta Thalassemia,” Journal of Pediatric Haematology/Oncology, Vol. 25, No. 11, 2003, pp. 880-884.
|http://dx.doi.org/10.1097/00043426-200311000-00011
[38] E. Y. Kwan, A. C. Lee, A. M. Li, S. C. Tam, C. F. Chan, Y. L. Lau and L. C. Low, “A Cross Sectional Study of Growth, Puberty and Endocrine Function in Patients with Thalassemia in Hong Kong,” Journal of Paediatrics and Child Health, Vol. 31, No. 2, 1995, pp. 83-87.
http://dx.doi.org/10.1111/j.1440-1754.1995.tb00752.x
[39] R. Chatterjee, T. N. Mukhopadhyay, S. Chandra and R. Bajoria, “Sex Steroid Priming for Induction of Puberty in Thalassemia Patients with Pulsatile Reversible Hypogonadotrophic Hypogonadism,” Hemoglobin, Vol. 35, No. 5-6, 2011, pp. 659-664.
http://dx.doi.org/10.3109/03630269.2011.630121
[40] E. Karahanyan, A. Stoyanova, I. Moumdzhiev and I. Ivanov, “Secondary Diabetes in Children with Thalassemia Major (Homozygous Thalassemia),” Folia Medica (Plovdiv), Vol. 36, No. 1, 1994, pp. 29-34.
[41] S. C. Finch and C. A. Finch, “Idiopathic Hemochromatosis: An Iron Storage Disease,” Medicine, Vol. 34, No. 4, 1955, pp. 381-430.
http://dx.doi.org/10.1097/00005792-195512000-00001
[42] M. N. Lassman, M. Genel, J. K. Wise, R. Hendler and P. Felig, “Carbohydrate Homeostasis and Pancreatic Islet Cell Function in Thalassemia,” Annals of Internal Medicine, Vol. 80, No. 1, 1974, pp. 65-69.
http://dx.doi.org/10.7326/0003-4819-80-1-65
[43] C. D. Saudek, R. M. Hemm and C. M. Peterson, “Abnormal Glucose Tolerance in Beta Thalassaemia Major,” Metabolism, Vol. 26, No. 1, 1977, pp. 43-52.
http://dx.doi.org/10.1016/0026-0495(77)90126-3
[44] J. P. Chern, K. H. Lin, M. Y. Lu, D. T. Lin, K. S. Lin, J. D. Chen and C. C. Fu, “Abnormal Glucose Tolerance in Transfusion Dependent β-Thalassemic Patients,” Diabetes Care, Vol. 24, No. 5, 2001, pp. 850-854.
http://dx.doi.org/10.2337/diacare.24.5.850
[45] M. R. Gamberini, M. Fortini, V. De Sanctis, G. Gilli and M. R. Testa, “Diabetes Mellitus and Impaired Glucose Tolerance in Thalassemia Major: Incidence, Prevalence, Risk Factors and Survival in Patients Followed in the Ferrara Centre,” Pediatric Endocrinology Reviews, Vol. 2, Suppl. 2, 2004, pp. 285-291.
[46] L. J. Noetzli, S. D. Mittelman, R. M. Watanabe, T. D. Coates and J. C. Wood, “Pancreatic Iron and Glucose Dysregulation in Thalassemia Major,” American Journal of Hematology, Vol. 87, No. 2, 2012, pp. 155-160.
http://dx.doi.org/10.1002/ajh.22223
[47] Y. Aydinok, S. Darcan, A. Polat, K. Kavakli, G. Nigli, M. Coker, M. Kantar and N. Cetingul, “Endocrine Complications in Patients with β Thalassemia Major,” Journal of Tropical Paediatrics, Vol. 48, No. 1, 2002, pp. 50-54.
http://dx.doi.org/10.1093/tropej/48.1.50
[48] M. Toumba, A. Sergis, C. Kanaris and N. Skordis, “Endocrine Complications in Patients with Thalassemia Major,” Pediatric Endocrinology Reviews, Vol. 5, No. 2, 2007, pp. 642-648.
[49] F. Najafipour, R. Sarisorkhabi, R. Bahrami, M. Zareizadeh, K. Ghoddousi, N. Aghamohamazadeh, A. Aliasgharzadeh, M. Mobaseri and M. Niafar, “Evaluation of Endocrine Disorders in Patients with Thalassemia Major,” Iranian Journal of Endocrinology and Metabolism, Vol. 10, No. 1, 2008, pp. 35-43.
[50] M. F. Messina, F. Lombardo, A. Meo, M. Miceli, M. Wasniewska, M. Valenzise, C. Ruggeri, T. Arrigo and F. De Luca, “Three-Year Prospective Evaluation of Glucose Tolerance, Beta-Cell Function and Peripheral Insulin Sensitivity in Nondiabetic Patients with Thalassemia Major,” Journal of Endocrinological Investigation, Vol. 25, No. 6, 2002, pp. 497-501.
[51] H. Cario, R. W. Holl, K. M. Debatin and E. Kohne, “Insulin Sensitivity and Beta-Cell Secretion in Thalassaemia Major with Secondary Haemochromatosis: Assessment by Oral Glucose Tolerance Test,” European Journal of Pediatrics, Vol. 162, No. 3, 2003, pp. 139-146.
[52] R. A. de Assis, A. A. Ribeiro, F. U. Kay, L. A. Rosemberg, C. H. Nomura, S. R. Loggetto, A. S. Araujo, A. F. Junior, M. P. de Almeida Veríssimo, G. R. Baldanzi, B. P. Espósito, R. H. Baroni, J. C. Wood and N. Hamerschlak, “Pancreatic Iron Stores Assessed by Magnetic Resonance Imaging (MRI) in Beta Thalassemic Patients,” European Journal of Radiology, Vol. 81, No. 7, 2012, pp. 1465-1470.
http://dx.doi.org/10.1016/j.ejrad.2011.03.077
[53] R. Toccafondi, M. Maioli and T. Meloni, “Plasma Insulin Response to Oral Carbohydrate in Cooley’s Anemia,” Rivista di Clinica Medica, Vol. 70, 1970, pp. 96-101.
[54] N. McIntosh, “Endocrinopathy in Thalassemia Major,” Archives of Disease in Childhood, Vol. 51, No. 3, 1976, pp. 195-201. http://dx.doi.org/10.1136/adc.51.3.195
[55] P. Cavallo-Perin, G. Pacini, F. Cerutti, A. Besone, C. Condo, L. Scachetti, A. Piga and G. Pagano, “Insulin Resistance and Hyperinsulinemia in Homozygous β Thalassemia,” Metabolism, Vol. 44, No. 3, 1995, pp. 281-286.
http://dx.doi.org/10.1016/0026-0495(95)90155-8
[56] Z. Siklar, F. E. Citak, Z. Uysal, G. ??al, M. Ertem, ?. Engiz, P. Ad?yaman, T. ?leri, S. G?zda?o?lu and M. Berbero?lu, “Evaluation of Glucose Homeostasis in Transfusion-Dependent Thalassemic Patients,” Pediatric Hematology-Oncology, Vol. 25, No. 7, 2008, pp. 630-637.
http://dx.doi.org/10.1080/08880010802313681
[57] E. P. Vichinsky, “The Morbidity of Bone Disease in Thalassaemia,” Annals of the New York Academy of Sciences, Vol. 850, 1998, pp. 344-348.
http://dx.doi.org/10.1111/j.1749-6632.1998.tb10491.x
[58] H. Cario, R. W. Holl, K. M. Debatin and E. Eohne, “Disproportionately Elevated Fasting Proinsulin Levels in Normoglycemic Patients with Thalassemia Major Are Correlated to the Degree of Iron Overload,” Hormone Research in Paediatrics, Vol. 59, No. 2, 2003, pp. 73-78.
http://dx.doi.org/10.1159/000068572
[59] K. Dmochowski, D. T. Finegood, W. Francombe, B. Tyler and B. Zinman, “Factors Determining Glucose Tolerance in Patients with Thalassemia Major,” Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 2, 1993, pp. 478-483.
[60] T. Arrigo, G. Crisaffilli, A. Meo, M. Sturiale, F. Lombardo, M. Micelli, D. Cucinotta and F. De Cuca, “Glucose Tolerance in Insulin Secretion and Peripheral Sensitivity in Thalassemia Major,” Journal of Pediatric Endocrinology & Metabolism, Vol. 11, Suppl. 3, 1998, pp. 863-866.
[61] M. Theochari, D. Loannidou, H. Nounopoulos, A. Bouloukos, M. Papadogiannis, M. Katsikari, T. Karpathios and C. S. Bartgocas, “Ultrasonography of the Pancreas as a Function Index in Children with Beta Thalassemia,” Journal of Pediatric Endocrinology and Metabolism, Vol. 13, No. 3, 2000, pp. 303-306.
http://dx.doi.org/10.1515/JPEM.2000.13.3.303
[62] V. De Sanctis, M. G. Zurlo, E. Senesi, C. Boffa, L. Cavallo and F. Di Gregorio, “Insulin Dependent Diabetes in Thalassemia,” Archives of Disease in Childhood, Vol. 63, No. 1, 1988, pp. 58-62.
http://dx.doi.org/10.1136/adc.63.1.58
[63] H. Landau, I. Matoth, Z. Landau-Cordova, A. Goldfarb, E. A. Rachmilewitz and B. Glaser, “Cross Sectional and Longitudinal Study of the Pituitary and Thyroid among Patients with Thalassemia Major,” Clinical Endocrinology, Vol. 38, No. 1, 1993, pp. 55-61.
http://dx.doi.org/10.1111/j.1365-2265.1993.tb00973.x
[64] S. Mariotti, F. Pigliaru, M. C. Cocco, A. Spiga, S. Vaquer and M. E. Lai, “β-Thalassemia and Thyroid Failure: Is There a Role for Thyroid Autoimmunity?” Pediatric Endocrinology Reviews, Vol. 8, Suppl. 2, 2011, pp. 307-309.
[65] V. De Sanctis, C. Vullo, L. Urso, F. Rigolin, A. Cavallini, K. Caramelli, C. Daugherty and N. Mazer, “Clinical Experience Using the Androderm Testosterone Transdermal System in Hypogonadal Adolescents and Young Men with Beta Thalassemia Major,” Journal of Pediatric Endocrinology and Metabolism, Vol. 11, Suppl. 3, 1998, pp. 891-900.
[66] V. C. Canale, P. Steinherz, M. New and M. Erlandson, “Endocrine Function in Thalassemia Major,” Annals of the New York Academy of Sciences, Vol. 232, 1974, pp. 333-345.
http://dx.doi.org/10.1111/j.1749-6632.1974.tb20597.x
[67] F. Oberklaid and R. Seshadri, “Hypoparathyroidism and the Other Endocrine Dysfunction Complicating Thalassemia Major,” Medical Journal of Australia, Vol. 1, No. 10, 1975, pp. 304-306.
[68] M. D. Fliynn, A. Fairley, T. Jackson and B. E. Clayton, “Hormonal Changes in Thalassemia Major,” Archives of Disease in Childhood, Vol. 51, No. 11, 1976, pp. 828-836.
http://dx.doi.org/10.1136/adc.51.11.828
[69] V. De Sanctis, R. Tanas, M. R. Gamberini, M. Sprocati, M. R. Govoni and M. Marsella, “Exaggerated TSH Response to TRH (‘Sub-Biochemical’ Hypothyroidism) in Prepubertal and Adolescent Thalassaemic Patients with Iron Overload: Prevalence and 20-Year Natural History,” Pediatric Endocrinology Reviews, Vol. 6, Suppl. 1, 2008, pp. 170-173.
[70] V. Chirico, A. Lacquaniti, V. Salpietro, N. Luca, V. Ferraù, B. Piraino, L. Rigoli, C. Salpietro and T. Arrigo, “Thyroid Dysfunction in Thalassemic Patients: Ferritin as Prognostic Marker and Combined Iron Chelators as Ideal Therapy,” European Journal of Endocrinology, 2013. [Epub ahead of print]
[71] A. Zervas, A. Katopodi, A. Protonotariou, S. Livadas, M. Karagiorga, C. Politis and G. Tolis, “Assessment of Thyroid Function in Two Hundred Patients with β-Thalassemia Major,” Thyroid, Vol. 12, No. 2, 2002, pp. 151-154.
http://dx.doi.org/10.1089/105072502753522383
[72] A. Filosa, S. Di Maio, G. Aloj and C. Acampora, “Longitudinal Study on Thyroid Function in Patients with Thalassemia Major,” Journal of Pediatric Endocrinology and Metabolism, Vol. 19, No. 12, 2006, pp. 1397-1404.
http://dx.doi.org/10.1515/JPEM.2006.19.12.1397
[73] S. Margo, P. Puzzanio, C. Consarino, M. C. Galati, S. Morgione, D. Porcelli, S. Grimaldi, D. Tancre, V. Arcuri, V. De Santis and A. Alberti, “Hypothyroidism in Patients with Thalassemia Syndromes,” Acta Haematologica, Vol. 84, No. 2, 1990, pp. 72-76.
http://dx.doi.org/10.1159/000205032
[74] G. Depaz, A. Deville, N. Coussement, J. Manassero and R. Mariani, “Thyroid Function in Thalassemia Major,” Annales de Pediatrie (Paris), Vol. 32, 1985, pp. 809-811.
[75] C. Phenekos, A. Karamerou, P. Pipis, M. Constantoulakis, J. Lasaridis, S. Detsi and K. Politou, “Thyroid Function in Patients with Homozygous β Thalassemia,” Clinical Endocrinology, Vol. 20, No. 4, 1984, pp. 445-450.
http://dx.doi.org/10.1111/j.1365-2265.1984.tb03440.x
[76] T. Alexandrides, N. Georgopoulos, S. Yarmenitis and A. G. Vagenakis, “Increased Sensitivity to the Inhibitory Function in Patients with Beta Thalassemia Major and Iron Overload and the Subsequent Development of Hypothyroidism,” European Journal of Endocrinology, Vol. 143, 2000, pp. 319-325.
http://dx.doi.org/10.1530/eje.0.1430319
[77] S. Mariotti, A. Loviselli, S. Murenu, F. Sau, L. Valentino, A. Mandas, S. Vacquer, E. Martino, A. Balestrieri and M. E. Lai, “High Prevalence of Thyroid Dysfunction in Adult Patients with Beta Thalassemia Major Submitted to Amiodarone Treatment,” Journal of Endocrinological Investigation, Vol. 22, No. 1, 1999, pp. 55-63.
[78] V. De Sanctis, M. Ughi, A. Pinamonti, M. Zachmann, T. Torresani, R. Gamberini, A. Di Palma, B. Bagni, A. R. Cavallini and C. Vullo, “Growth Retardation in Thalassemia Major,” In: A. Prader and R. Rappaport, Eds., Clinical Issues in Growth Disorders: Evaluation, Diagnosis and Therapy, Freund publishing House Ltd., London, 1994, pp. 31-47.
[79] M. P. Senanayalee, S. A. Suraweera and H. D. Hubert, “Thyroid Function in Thalassemia Major,” Ceylon Medical Journal, Vol. 44, No. 4, 1999, pp. 166-168.
[80] G. Zamboni, P. Marradi, F. Tagliaro, R. Dorizzi and L. Tatò, “Parathyroid Hormone, Calcitonin and Vitamin D Metabolites in Beta-Thalassaemia Major,” European Journal of Pediatrics, Vol. 145, No. 1-2, 1986, pp. 133-136.
http://dx.doi.org/10.1007/BF00441875
[81] L. Even, T. Bader and Z. Hochbeg, “Diurnal Variation of Serum Calcium, Phosporus and PTH in the Diagnosis of Hypoparathyroidism,” Pediatric Research (Abstract), 2001, pp. 3-141.
[82] N. G. Angelopoulos, A. Goula, G. Rombopoulos, V. Kaltzidou, E. Katounda, D. Kaltsas and G. Tolis, “Hypoparathyroidism in Transfusion Dependant Patients with β Thalassemia,” Journal of Bone and Mineral Metabolism, Vol. 24, No. 2, 2006, pp. 138-145.
http://dx.doi.org/10.1007/s00774-005-0660-1
[83] A. Aleem, A. K. Al-Momem, M. Al-Harakati, A. Hassan and I. Al-Fawaz, “Hypocalcaemia Due to Hypoparathyroidism in β Thalassemia Major Patients,” Annals of Saudi Medicine, Vol. 20, No. 5-6, 2000, pp. 364-366.
[84] F. Perignon, R. Brauner, J. C. Souberbielle, M. De Montalembert and R. Girot, “Growth and Endocrine Function in Major Thalassemia,” Archives Fran?aises de Pédiatrie, Vol. 50, No. 8, 1993, pp. 657-663.
[85] C. Vullo, V. De Sanctis, M. Katz, B. Wonke, A. V. Hoffbrand, B. Bagni, T. Torressani, G. Tolis, M. Masiero, A. Di Palma and L. Borgatti, “Endocrine Abnormalities in Thalassemia,” Annals of the New York Academy of Sciences, Vol. 612, 1990, pp. 293-310.
http://dx.doi.org/10.1111/j.1749-6632.1990.tb24317.x
[86] V. De Sanctis and B. Wonke, “Growth and Endocrine Complications,” In: Growth and Endocrine Complications in Thalassemia, Mediprint, Roma, 1998, pp. 17-30.
[87] M. Goyal, P. Abrol and H. Lal, “Parathyroid and Calcium Status in Patients with Thalassemia,” Indian Journal of Clinical Biochemistry, Vol. 25, No. 4, 2010, pp. 385-387.
http://dx.doi.org/10.1007/s12291-010-0071-5
[88] K. A. Autio, J. E. Mait, M. Lesser and P. J. Giardina, “Low Bone Mineral Density in Adolescents with β-Thalassemia,” Annals of the New York Academy of Sciences, Vol. 1054, 2005, pp. 462-466.
http://dx.doi.org/10.1196/annals.1345.063
[89] N. Bhamarapravati, S. Na-Nakorn, P. Wasi and S. Tuchinda, “Pathology of Beta Thalassemia Haemoglobin E Disease,” American Journal of Clinical Pathology, Vol. 47, 1967, pp. 745-758.
[90] M. Scacchi, L. Danesi, A. Cattaneo, E. Valassi, F. Pecori Giraldi, P. Radaelli, A. Ambrogio, E. D’Angelo, N. Mirra, L. Zanaboni, M. D. Cappellini and F. Cavagnini, “The Pituitary-Adrenal Axis in Adult Thalassaemic Patients,” European Journal of Endocrinology, Vol. 162, No. 1, 2010, pp. 43-48. http://dx.doi.org/10.1530/EJE-09-0646
[91] C. A. Sklar, L. Q. Lew, D. J. Yoon and R. David, “Adrenal Function in Thalassemia Major Following Long-Term Treatment with Multiple Transfusions and Chelation Therapy. Evidence for Dissociation of Cortisol and Adrenal Androgen Secretion,” American Journal of Diseases of Children, Vol. 141, No. 3, 1987, pp. 327-330.
http://dx.doi.org/10.1001/archpedi.1987.04460030105036
[92] P. Pasqualetti, D. Colantino, A. Collacciani, R. Casale and G. Natali, “Circadian Pattern of circulating Plasma ACTH, Cortisol and Aldosterone in Patients with Beta Thalassemia,” Acta Endocrinologica, Vol. 123, No. 2, 1990, pp. 174-178.
[93] P. Poomthavorn, B. Isaradisaikul, A. Chuansumrit, P. Khlairit, A. Sriphrapradang and P. Mahachoklertwattana, “High Prevalence of ‘Biochemical’ Adrenal Insufficiency in Thalassemics: Is It a Matter of Different Testings or Decreased Cortisol Binding Globulin?” Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 10, 2010, pp. 4609-4615. http://dx.doi.org/10.1210/jc.2010-0205
[94] E. Drakonaki, O. Papakonstantinou, T. Maris, A. Vasiliadou, A. Papadakis and N. Gourtsoyiannis, “Adrenal Glands in Beta-Thalassemia Major: Magnetic Resonance (MR) Imaging Features and Correlation with Iron Stores,” European Radiology, Vol. 15, No. 12, 2005, pp. 2462-2468.
http://dx.doi.org/10.1007/s00330-005-2855-1
[95] V. De Sanctis, S. Stea, L. Savarino, D. Granchi, M. Visentin, M. Sprocati, R. Govoni and A. Pizzoferrato, “Osteochondrodystrophic Lesions in Chelated Thalassemic Patients: An Histological Analysis,” Calcified Tissue International, Vol. 67, No. 2, 2000, pp. 134-140.
http://dx.doi.org/10.1007/s00223001121
[96] C. E. Jensen, S. M. Tuck, J. E. Aquen, S. Koneru, R. W. Morris, A. Yardumian, E. Prescott, A. V. Hoffbrand and B. Wonke, “High Prevalence of Low Bone Mass in Thalassemia Major,” British Journal of Haematology, Vol. 103, No. 4, 1998, pp. 911-915.
http://dx.doi.org/10.1046/j.1365-2141.1998.01108.x
[97] A. Filosa, A. Di Maios, A. Saviano, S. Vocca and G. Esposito, “Can Adrenarche Influence the Degree of Osteopenia in Thalassemic Children?” Journal of Pediatric Endocrinology and Metabolism, Vol. 9, No. 3, 1996, pp. 401-406.
http://dx.doi.org/10.1515/JPEM.1996.9.3.401
[98] L. Ruggiero and V. De Sanctis, “Multicentre Study on Prevalence of Fractures in Transfusion Dependent Thalassemic Patients,” Journal of Pediatric Endocrinology and Metabolism, Vol. 11, Suppl. 3, 1998, pp. 773-778.
[99] E. Molyvda-Athanassopoulou, A. Sioundas, N. Karatzas, M. Aggellaki, K. Pazaitou and I. Vainas, “Bone Mineral Density of Patients with Thalassemia Major: Four Year Follow Up,” Calcified Tissue International, Vol. 64, No. 6, 1999, pp. 481-484.
http://dx.doi.org/10.1007/s002239900637
[100] E. Voskaridou, M. C. Kyrtsonis, E. Terpos, M. Skordili, I. Theodoropoulos, A. Bergele, E. Diamanti, A. Kalovidouris, A. Loutradi and D. Loukopoulos, “Bone Resorption Is Increased in Young Adults with Thalassemia Major,” British Journal of Haematology, Vol. 112, No. 1, 2001, pp. 36-41.
http://dx.doi.org/10.1046/j.1365-2141.2001.02549.x
[101] M. G. Vogiatzi, K. A. Autio, J. E. Mait, R. Schneider, M. Lesser and P. Giardina, “Low Bone Mineral Density in Adolescents with (Beta) Thalassemia,” Annals of the New York Academy of Sciences, Vol. 1054, 2005, pp. 462-466.
http://dx.doi.org/10.1196/annals.1345.063

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.